急性髓系白血病(AML)起源于体内少量存在的白血病干细胞(LSC),由于LSC对化疗耐药导致疾病难治、复发,研究靶向LSC的特异性治疗方法有利于减少疾病复发甚至可治愈疾病.随着对LSC生物学特征认识的不断加深,针对LSC的靶向治疗研究相继展开,这些靶向治疗主要包括靶向LSC表面分子、信号转导通路及LSC的微环境等.文章对AML的LSC靶向治疗进展进行总结.%Acute myeloid leukemia (AML) originates from rare leukemia stem cells (LSC).Because these chemotherapy-resistant LSC are thought to underlie disease relapse,effective therapeutic strategies specifically targeting these cells may be beneficial.With the increasing knowledge regarding the LSC,several major directions in targeted therapies with regard to LSC are being investigated.These include targeting cell surface molecules,signal pathways,and microenvironment of LSC.Since eliminating LSC-should provide an efficient,potentially curative treatment option for leukemia patients,this article reviews the recent progress of LSC targeting in AML therapy.
展开▼